Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bios.2020.112316 http://scihub22266oqcxt.onion/10.1016/j.bios.2020.112316 32553350!7245202!32553350     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biosens+Bioelectron 2020 ; 164 (ä): 112316 Nephropedia Template TP {{tp|p=32553350|t=2020. Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis |pdf=|usr=}}{{32553350}} gab.com Text Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis JO: Biosens Bioelectron http://www.kidney.de/pget.php?&tw=1&pmid=32553350 #FOAvip Recent research suggests that SARS-CoV-2-infected individuals can be highly infectious while asymptomatic or pre-symptomatic, and that an infected person may infect 5.6 other individuals on average. This situation highlights the need for rapid, sensitive SARS-CoV-2 diagnostic assays capable of high-throughput operation that can preferably utilize existing equipment to facilitate broad, large-scale screening efforts. We have developed a CRISPR-based assay that can meet all these criteria. This assay utilizes a custom CRISPR Cas12a/gRNA complex and a fluorescent probe to detect target amplicons produced by standard RT-PCR or isothermal recombinase polymerase amplification (RPA), to allow sensitive detection at sites not equipped with real-time PCR systems required for qPCR diagnostics. We found this approach allowed sensitive and robust detection of SARS-CoV-2 positive samples, with a sample-to-answer time of ~50 min, and a limit of detection of 2 copies per sample. CRISPR assay diagnostic results obtained nasal swab samples of individuals with suspected COVID-19 cases were comparable to paired results from a CDC-approved quantitative RT-PCR (RT-qPCR) assay performed in a state testing lab, and superior to those produced by same assay in a clinical lab, where the RT-qPCR assay exhibited multiple invalid or inconclusive results. Our assay also demonstrated greater analytical sensitivity and more robust diagnostic performance than other recently reported CRISPR-based assays. Based on these findings, we believe that a CRISPR-based fluorescent application has potential to improve current COVID-19 screening efforts. Twit Text FOAVip Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis ????Biosens Bioelectron http://www.kidney.de/pget.php?&tw=1&pmid=32553350 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32553350 #FOAvip English Wikipedia <ref>{{Cite pmid|32553350}}</ref> Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis #MMPMID32553350 Huang Z; Tian D; Liu Y; Lin Z; Lyon CJ; Lai W; Fusco D; Drouin A; Yin X; Hu T; Ning B Biosens Bioelectron 2020[Sep]; 164 (ä): 112316 PMID32553350show ga Recent research suggests that SARS-CoV-2-infected individuals can be highly infectious while asymptomatic or pre-symptomatic, and that an infected person may infect 5.6 other individuals on average. This situation highlights the need for rapid, sensitive SARS-CoV-2 diagnostic assays capable of high-throughput operation that can preferably utilize existing equipment to facilitate broad, large-scale screening efforts. We have developed a CRISPR-based assay that can meet all these criteria. This assay utilizes a custom CRISPR Cas12a/gRNA complex and a fluorescent probe to detect target amplicons produced by standard RT-PCR or isothermal recombinase polymerase amplification (RPA), to allow sensitive detection at sites not equipped with real-time PCR systems required for qPCR diagnostics. We found this approach allowed sensitive and robust detection of SARS-CoV-2 positive samples, with a sample-to-answer time of ~50 min, and a limit of detection of 2 copies per sample. CRISPR assay diagnostic results obtained nasal swab samples of individuals with suspected COVID-19 cases were comparable to paired results from a CDC-approved quantitative RT-PCR (RT-qPCR) assay performed in a state testing lab, and superior to those produced by same assay in a clinical lab, where the RT-qPCR assay exhibited multiple invalid or inconclusive results. Our assay also demonstrated greater analytical sensitivity and more robust diagnostic performance than other recently reported CRISPR-based assays. Based on these findings, we believe that a CRISPR-based fluorescent application has potential to improve current COVID-19 screening efforts. |*CRISPR-Cas Systems[MESH] |Base Sequence[MESH] |Betacoronavirus/genetics/*isolation & purification[MESH] |Biosensing Techniques/methods/statistics & numerical data[MESH] |COVID-19[MESH] |Coronavirus Infections/*diagnosis/virology[MESH] |Fluorescent Dyes[MESH] |Genes, Viral[MESH] |High-Throughput Nucleotide Sequencing/methods/statistics & numerical data[MESH] |Humans[MESH] |Nucleic Acid Amplification Techniques/methods/statistics & numerical data[MESH] |Pandemics[MESH] |Pneumonia, Viral/*diagnosis/virology[MESH] |Predictive Value of Tests[MESH] |RNA, Viral/analysis/genetics[MESH] |Reproducibility of Results[MESH] |Reverse Transcriptase Polymerase Chain Reaction/methods/statistics & numerical data[MESH] |SARS-CoV-2[MESH]Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis(epmc).pdf DeepDyve Pubget Overpricing